The decision as to whether administer adjuvant chemotherapy for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is becoming increasingly complex1–4. This evidence concerns the gene ERBB2 and breast cancer.